NMD4C Hire Research Software Developer

New Research Software Developer

The NMD4C are pleased to announce the hiring of research software developer Kevin LaFleur to the network’s biobanking team! Kevin holds a bachelor’s degree in music and cognitive science from McGill University and brings experience from technical and research assistant roles at labs and research groups in Montreal and Boston, most recently at Tore Nielsen’s Dream and Nightmare Lab at UdeM.

Find out more about the NMD4C’s Biobanking work!

Role of the Developer

As a research software developer for the NMD4C and the Montreal Neurological Institute, Kevin works with Dr. Jason Karamchandani to develop the technical infrastructure for a centralized Canadian neuromuscular biobanking catalogue. Kevin works to link biospecimen, imaging and genetic information from neuromuscular biobanks across Canada to a central repository within the Neuro’s C-BIG project.

welcome to the team - Kevin LaFleur

Read next...

NEWS Website Featured Images

Call for Applications: Join the NMD4C Basic Science Trainee Committee (BSTC)

We are now accepting applications from graduate students, research trainees, and postdoctoral fellows working in neuromuscular labs in Canada.

NMD4C's BSTC launches SOP database

Basic Science Trainee Committee Launches Pre-Clinical Science Standard Operating Procedures

We’re pleased to announce the launch of the BSTC Standard Operating Procedures (SOPs), now available through the NMD4C Resource Hub. These SOPs provide standardized guidance for laboratories, clinics, and research programs across Canada, supporting consistent, high-quality neuromuscular care and research. Explore the full SOP Library and other open-access resources designed to advance collaboration and strengthen practices nationwide.

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 26-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!